Crown Bioscience Inc.
Crown Bioscience is a global contract research organization (CRO) specializing in oncology, immuno-oncology, hematological disorders, and drug discovery. Their mission is to empower customers to improve human health through innovative services, scientific talent, and high standards. They offer preclinical, translational, and advanced in vitro and in vivo models, including patient-derived xenograft (PDX), organoid, and 3D bone marrow niche models, to support drug discovery and development. Their platforms and services are designed to accelerate the development of new therapies, reduce reliance on animal models, and provide clinically relevant data.
Industries
Nr. of Employees
large (251-1000)
Crown Bioscience Inc.
16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, USA
Patents
Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
US-10442862-B2
View DetailsAdministration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer
US-10413538-B2
View DetailsMethods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin
US-8722886-B1
View Details
Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
US-10442862-B2
View DetailsAdministration of karenitecin for the treatment of platinum and/or taxane chemotherapy-resistant or -refractory advanced ovarian cancer
US-10413538-B2
View DetailsMethods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin
US-8722886-B1
View DetailsProducts
Preclinical model and sample databases (PDX, xenograft, syngeneic, organoid)
Curated databases of preclinical models and available biospecimens for study selection and model matching to therapeutic programs, with searchable metadata to enable rapid model identification.
Organotypic 3D bone marrow niche models
In vitro 3D bone marrow niche models using bioactive hydrogels and stromal-endothelial networks designed for hematological malignancy screening, hematopoietic toxicity testing and evaluation of bone marrow-targeting therapies.
Mouse clinical trial datasets and model panels
Structured datasets and model panels derived from mouse clinical trials to support biomarker identification and translational analyses.
Spatial transcriptomics service (barcoded-slide whole-transcriptome)
Sequencing-based spatial gene expression mapping workflows compatible with FFPE and fresh frozen tissue, producing spatially resolved whole-transcriptome data integrated with histology.
Preclinical model and sample databases (PDX, xenograft, syngeneic, organoid)
Curated databases of preclinical models and available biospecimens for study selection and model matching to therapeutic programs, with searchable metadata to enable rapid model identification.
Organotypic 3D bone marrow niche models
In vitro 3D bone marrow niche models using bioactive hydrogels and stromal-endothelial networks designed for hematological malignancy screening, hematopoietic toxicity testing and evaluation of bone marrow-targeting therapies.
Mouse clinical trial datasets and model panels
Structured datasets and model panels derived from mouse clinical trials to support biomarker identification and translational analyses.
Spatial transcriptomics service (barcoded-slide whole-transcriptome)
Sequencing-based spatial gene expression mapping workflows compatible with FFPE and fresh frozen tissue, producing spatially resolved whole-transcriptome data integrated with histology.
Services
Design, execution and analysis of in vivo oncology studies using PDX, CDX, syngeneic, humanized and orthotopic models, including efficacy, pharmacology and safety endpoints.
Development and testing of 2D and 3D in vitro assays including organoids, tumoroids, co-cultures and high-content imaging readouts for target validation and lead selection.
Ex vivo drug screening and hematopoietic toxicity assessment using bioactive hydrogel-based 3D bone marrow niche models that include stromal and endothelial compartments and support patient-derived cells and immune cell co-cultures.
Acquisition, processing and long-term storage of human biospecimens, including longitudinal plasma collections to support biomarker research and translational studies.
End-to-end genomics services including NGS library preparation, sequencing and computational analysis such as RNA-seq panels and cell line authentication.
Sequencing- and probe-based spatial transcriptomics workflows and multiplex immunohistochemistry combined with image analysis to map gene and protein expression in histological context for biomarker discovery and tissue-based analyses (FFPE and fresh-frozen compatible).
Design, execution and analysis of in vivo oncology studies using PDX, CDX, syngeneic, humanized and orthotopic models, including efficacy, pharmacology and safety endpoints.
Development and testing of 2D and 3D in vitro assays including organoids, tumoroids, co-cultures and high-content imaging readouts for target validation and lead selection.
Ex vivo drug screening and hematopoietic toxicity assessment using bioactive hydrogel-based 3D bone marrow niche models that include stromal and endothelial compartments and support patient-derived cells and immune cell co-cultures.
Acquisition, processing and long-term storage of human biospecimens, including longitudinal plasma collections to support biomarker research and translational studies.
End-to-end genomics services including NGS library preparation, sequencing and computational analysis such as RNA-seq panels and cell line authentication.
Sequencing- and probe-based spatial transcriptomics workflows and multiplex immunohistochemistry combined with image analysis to map gene and protein expression in histological context for biomarker discovery and tissue-based analyses (FFPE and fresh-frozen compatible).
Expertise Areas
- Oncology and immuno-oncology preclinical research
- Preclinical model development (PDX, CDX, syngeneic, humanized, organoids)
- Hematological disease modeling and 3D bone marrow niche assays
- Biomarker discovery and translational biomarker strategy
Key Technologies
- Patient-derived xenograft (PDX) models
- Humanized genetically engineered mouse models
- Organoids and 3D culture systems
- 3D bioactive hydrogel scaffolds and pre-vascularized cultures
News & Updates
Crown Bioscience was awarded for outstanding collaboration, communication, and commitment to clients, demonstrating leadership in the CRO industry.
The Leiden, Netherlands facility earned the highest level of certification in the My Green Lab program, demonstrating eco-friendly laboratory management.
The partnership with NEXT Oncology has been extended, supporting oncology drug development and leveraging patient-derived models.
John Gu has been appointed as the new Chief Executive Officer, bringing extensive experience in digital strategy, business transformation, and genomic data analysis.
Recognition for innovative drug development solutions.
Award for outstanding client service and partnership in CRO industry.
Crown Bioscience was awarded for outstanding collaboration, communication, and commitment to clients, demonstrating leadership in the CRO industry.
The Leiden, Netherlands facility earned the highest level of certification in the My Green Lab program, demonstrating eco-friendly laboratory management.
The partnership with NEXT Oncology has been extended, supporting oncology drug development and leveraging patient-derived models.
John Gu has been appointed as the new Chief Executive Officer, bringing extensive experience in digital strategy, business transformation, and genomic data analysis.
Recognition for innovative drug development solutions.
Award for outstanding client service and partnership in CRO industry.